<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106731">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01714921</url>
  </required_header>
  <id_info>
    <org_study_id>CEN_G_CA_13</org_study_id>
    <nct_id>NCT01714921</nct_id>
  </id_info>
  <brief_title>Protecta Smart Analysis Register</brief_title>
  <acronym>ProSA</acronym>
  <official_title>ProSA Protecta Smart Analysis Register</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination of application and efficacy of Smart Shock algorithm in ICD patients
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the relative reduction of shock related episodes with Smart shock technology</measure>
    <time_frame>24 months</time_frame>
    <description>Effectiveness will be measured by the aim of Smart Shock algorithms: the reduction of shocks. Utilisation will be measured by the programming of Smart Shock algorithms and detection of tachycardia, the deviance from nominal parameters and the application of Smart Shock algorithms. To get impression of the necessarity for ICD therapy in these patients, the risk of ventricular and atrial arrhythmia will be examined in the patient population included in the study. To determine the effect of Smart Shock technology, the relative fraction of episodes which are not treated by shock delivery due to Smart Shock, will be measured. It is assumed, that a total 95% confidence interval of 10% is sufficient from a medical point of view.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of relative shock reduction due to Smart shock technology</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of VF episodes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of not known AT/AF,</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>programming vs. nominal parameters dependant of baseline data</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">428</enrollment>
  <condition>Focus of Study is Efficacy of Smart Shock Algorithm in ICD Patients</condition>
  <arm_group>
    <arm_group_label>Smart shock technology</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that suffuse the inclusion criteria and signed the informed consent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients implanted an Implantable Cardioverter Defibrillator (ICD) with smart shock
             algorithm

          -  written informed consent

        Exclusion Criteria:

          -  patients with life expectancy less than 24 months

          -  patients younger than 18 years

          -  pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 22, 2015</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
